lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181ООО «Издательство "Открытые системы"»10.51793/OS.2025.28.1.009lvrach-1350Research ArticleСОБЫТИЕEVENTРоль ботулинотерапии в комплексном восстановлении пациентов после инсультаThe role of botulinum therapy in the complex recovery of patients after strokeЧирковаМ. В.ChirkovaM. V.

Чиркова Марина Витальевна - редактор журнала «Лечащий Врач».

123056, Москва, а/я 82

Marina V. Chirkova - editor of The Lechaschy Vrach journal.

a/z 82 Moscow, 123056

mara@osp.ruЖурнал «Лечащий Врач»РоссияThe Lechaschy Vrach journalRussian Federation202525012025016064Copyright © Чиркова М.В., 20252025Чиркова М.В.Chirkova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/1350Введение

Введение. 10-12 октября 2024 года в Москве прошел II Всероссийский нейроконгресс с международным участием. Основные научные направления Конгресса включали следующие темы: острые и хронические нарушения мозгового кровообращения, эпилепсия и пароксизмальные состояния, инфекционные заболевания нервной системы, когнитивные нарушения, наследственные дегенеративные заболевания нервной системы, травмы головного и спинного мозга, реабилитация при заболеваниях нервной системы, неврология пожилого возраста, новые технологии в диагностике и лечении инсульта и многое другое.

Результаты

Результаты. На состоявшемся в рамках конгресса сателлитном симпозиуме ООО «Мерц Фарма» «Организация реабилитации постинсультных пациентов со спастичностью на региональном уровне» обсуждались новейшие подходы к восстановлению пациентов, перенесших инсульт.

Background

Background. The II All-Russian Neurocongress with international participation was held in Moscow on 10-12 October 2024. The main scientific directions of the Congress included the following topics: acute and chronic cerebral circulatory disorders, epilepsy and paroxysmal states, infectious diseases of the nervous system, cognitive disorders, hereditary degenerative diseases of the nervous system, traumas of the brain and spinal cord, rehabilitation in diseases of the nervous system, neurology of the elderly, new technologies in the diagnosis and treatment of stroke and many others.

Results

Results. At the satellite symposium of Merz Pharma LLC ‘Organisation of rehabilitation of post-stroke patients with spasticity at the regional level’ held within the framework of the congress, the latest approaches to rehabilitation of stroke patients were discussed.

инсультспастичностьреабилитацияновые технологииботулинотерапияstrokespasticityrehabilitationnew technologiesbotulinum therapyReferencesOpheim A., Danielsson A., Murphy M. A., et al. Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil. 2014; 93 (10): 884-896. DOI: 10.1097/PHM.0000000000000157.Opheim A., Danielsson A., Murphy M. A., et al. Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil. 2014; 93 (10): 884-896. DOI: 10.1097/PHM.0000000000000157.Wissel J., Manack A., Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013; 80 (3 Suppl 2): S13-19. DOI: 10.1212/WNL.0b013e3182762448.Wissel J., Manack A., Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013; 80 (3 Suppl 2): S13-19. DOI: 10.1212/WNL.0b013e3182762448.Lundström E., Smits A., Terént A., Borg J. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med. 2010; 42: 296-301.Lundström E., Smits A., Terént A., Borg J. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med. 2010; 42: 296-301.Li Sh., Francisco G. E., Rymer W. Z. A new defenition of poststroke spasticity and the interference of spasticity with motor recovery from acute to chronic stages. Neurorehabil Neural Repair. 2021; 35 (7): 601-610. DOI: 10.1177/15459683211011214.Li Sh., Francisco G. E., Rymer W. Z. A new defenition of poststroke spasticity and the interference of spasticity with motor recovery from acute to chronic stages. Neurorehabil Neural Repair. 2021; 35 (7): 601-610. DOI: 10.1177/15459683211011214.Marsden J., Stevenson V., Jarrett L. Treatment of spasticity. Handb Clin Neurol. 2023;196: 497-521. DOI: 10.1016/B978-0-323-98817-9.00010-7.Marsden J., Stevenson V., Jarrett L. Treatment of spasticity. Handb Clin Neurol. 2023;196: 497-521. DOI: 10.1016/B978-0-323-98817-9.00010-7.Triccas L. T., Kennedy N., Smith T., Pomeroy V. Predictors of upper limb spasticity after stroke? A systematic review and meta-analysis. Physiotherapy. 2019; 105 (2): 163-173. DOI: 10.1016/j.physio.2019.01004.Triccas L. T., Kennedy N., Smith T., Pomeroy V. Predictors of upper limb spasticity after stroke? A systematic review and meta-analysis. Physiotherapy. 2019; 105 (2): 163-173. DOI: 10.1016/j.physio.2019.01004.Gohritz A., Jan Fridén J. Management of Spinal Cord Injury-Induced Upper Extremity Spasticity. Hand Clin. 2018; 34 (4): 555-565. DOI: 10.1016/j.hcl.2018.07.001.Gohritz A., Jan Fridén J. Management of Spinal Cord Injury-Induced Upper Extremity Spasticity. Hand Clin. 2018; 34 (4): 555-565. DOI: 10.1016/j.hcl.2018.07.001.Halabchi F., Alizadeh Z., Sahraian M. A., Abolhasani M. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol. 2017; 17 (1): 185. DOI: 10.1186/s12883-017-0960-9.Halabchi F., Alizadeh Z., Sahraian M. A., Abolhasani M. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol. 2017; 17 (1): 185. DOI: 10.1186/s12883-017-0960-9.Kong K. H., Lee J., Chua K. S. Occurrence and temporal evolution of upper limb spasticity in stroke patients admitted to a rehabilitation unit. Arch Phys Med Rehabil. 2012; 93 (1): 143-148. DOI: 10.1016/j.apmr.2011.06.027.Kong K. H., Lee J., Chua K. S. Occurrence and temporal evolution of upper limb spasticity in stroke patients admitted to a rehabilitation unit. Arch Phys Med Rehabil. 2012; 93 (1): 143-148. DOI: 10.1016/j.apmr.2011.06.027.Инструкции по применению препаратов, 2024.Instructions for use, 2024. (In Russ.)Kaňovský P., Slawek J., Denes Z., et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011; 43 (6): 486-492. DOI: 10.2340/16501977-0796.Kaňovský P., Slawek J., Denes Z., et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011; 43 (6): 486-492. DOI: 10.2340/16501977-0796.Elovic E. P., Munin M. C., Kaňovský P., et al. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle & Nerve. 2016; 53 (3): 415-421. DOI: 10.1002/mus.24776.Elovic E. P., Munin M. C., Kaňovský P., et al. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle & Nerve. 2016; 53 (3): 415-421. DOI: 10.1002/mus.24776.Kaňovský P., Elovic E. P., Angelika Hanschmann A., et al. Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis. Front Neurol. 2021; 11: 615706. DOI: 10.3389/fneur.2020.615706.Kaňovský P., Elovic E. P., Angelika Hanschmann A., et al. Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis. Front Neurol. 2021; 11: 615706. DOI: 10.3389/fneur.2020.615706.Wissel J., Bensmail D., Ferreira J. J., et al. Safety and efficacy of incobotulinum toxin A doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017; 88 (14): 1321-1328. DOI: 10.1212/WNL.0000000000003789.Wissel J., Bensmail D., Ferreira J. J., et al. Safety and efficacy of incobotulinum toxin A doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017; 88 (14): 1321-1328. DOI: 10.1212/WNL.0000000000003789.Wissel J., Camões-Barbosa A., Comes G., et al. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021; 13 (12): 887. DOI: 10.3390/toxins13120887.Wissel J., Camões-Barbosa A., Comes G., et al. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021; 13 (12): 887. DOI: 10.3390/toxins13120887.Костенко Е. В.,Петрова Л. В. ,Ганжула П. А. и др. Опыт применения Rсеомина в коррекции спастичности руки в ранний восстановительный период инсульта. Журнал неврологии и психиатрии им. С. С. Корсакова. 2012; 112; 2: 29-34.Kostenko E. V., Petrova L. V. Ganzhula P. A., et al. Experience of using Rseomin in the correction of hand spasticity in the early recovery period of stroke. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova 2012; 112; 2: 29-34. (In Russ.)Коваленко А. П., Вознюк И. А., Наумов К. М. и др. Лечение спастичности у пациентов с последствиями черепно-мозговой травмы. Неврология, нейропсихиатрия, психосоматика. 2022. 14 (1): 26-31. https://doi.org/10.14412/2074-2711-2022-1-26-31.Kovalenko A. P., Vozniuk I. A., Naumov K. M., et al. Treatment of spasticity in patients with the consequences of traumatic brain injury. Nevrologiya, neiropsikhiatriya, psikhosomatika. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (1): 26-31. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-26-31Peter P. Urban, Thomas Wolf. http://ahajournals.orgPeter P. Urban, Thomas Wolf. http://ahajournals.orgХатькова С. Е., Орлова О. Р., Боцина А. Ю. и др. Основные принципы ведения пациентов с нарушением мышечного тонуса после очагового повреждения головного мозга. Consilium Medicum. 2016. 18 (2.1): 25-33.Khatkova S.E., Orlova O. R., Botsina A. Yu., et al. Basic principles of management of patients with impaired muscle tone after focal brain injury. Consilium Medicum. 2016. 18 (2.1): 25-33. (In Russ.)Hefter H., Rosenthal D., Jansen A., et al. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. Journal of Neurology. 2023. 270 (2): 788-796. DOI: 10.1007/s00415-022-11395-2.Hefter H., Rosenthal D., Jansen A., et al. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. Journal of Neurology. 2023. 270 (2): 788-796. DOI: 10.1007/s00415-022-11395-2.

The authors declare that there are no conflicts of interest present.